ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ACAD 40.55
price chart
Needham Maintains Buy on ACADIA Pharmaceuticals Inc.; Here's Why
In a research report released Friday, Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $38 price target, after the company reported first-quarter financial results and held a conference call last ...
Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader ...  TheStreet.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a Buy: Needham  Markets.co
Analysts Remain Bullish on ACADIA Pharmaceuticals Inc. Despite Drug ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is making headlines with the sudden announcement of the CEO's retirement and an application delay for the company's leading drug.
Acadia Pharmaceuticals Buyout Will Happen, Just Not Yet (ACAD)  Seeking Alpha (registration)
Acadia Surges as Canceled Events Lead to Deal Speculation  Bloomberg
DEADLINE ALERT: Rigrodsky & Long, PA Reminds Shareholders Of ACADIA ...
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ GS: ACAD) of an upcoming deadline involving a securities ...
ACADIA Pharmaceuticals Stock Rating Upgraded by Vetr Inc. (ACAD)
ACADIA Pharmaceuticals logo ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by stock analysts at Vetr from a “hold” rating to a “buy” rating in a report issued on Monday.
ACADIA Pharmaceuticals Upgraded to Buy at Vetr Inc. (ACAD)  The Legacy
Closing Bell Reports: ARRIS Group, Inc. (ARRS), ACADIA Pharmaceuticals Inc ...  WallStreet Scope
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Acadia ...
To: All persons or entities who purchased or otherwise acquired common shares of ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) between February 26, 2015 and March 11, 2015.
Biotech Stocks in News - PDL BioPharma (PDLI), ACADIA Pharmaceuticals ...
PDL BioPharma Inc (NASDAQ:PDLI) gained +1.07% to close last trading session at $6.64. The company, on May 06, 2015, declared financial results for the first quarter ended March 31, 2015.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Inflow of Net Money ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -1.02% or -0.41 points to trade at $39.83 per share. As per the latest trading data available, the net money flow stood at $4.85 million as the counter received $14.56 million in upticks and gave away ...
ACADIA Pharmaceuticals (ACAD) - Investment Analysts' Recent Ratings Updates  WKRB News
Closing Bell Reports: ACADIA Pharmaceuticals Inc. (ACAD), Fortune Brands ...  WallStreet Scope
Biotech Equities Technical Study -- Gilead Sciences, Celgene, Novavax, Arena ...
Over the last one month and over the past three months, ACADIA Pharmaceuticals Inc.'s shares have advanced 3.00% and 11.82%, respectively.
Acadia Pharmaceuticals Moves Up In Market Cap Rank, Passing QEP Resources
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc ...
ACADIA Pharmaceuticals Inc.: ACADIA Pharmaceuticals to Announce First ...
SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological ...
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7 ...  MarketWatch
ACADIA Pharmaceuticals Upgraded at Vetr Inc. (ACAD)  sleekmoney